Utilizing combination therapy for ethnic skin.
A major issue in treating acne in individuals of color is the need to treat and prevent postinflammatory hyperpigmentation (PIH), which is common in this population. This subset analysis reports the pigmentary changes in subjects of color with acne who were enrolled in a community-based trial comparing 3 different topical therapeutic regimens. All subjects received combination clindamycin 1%-benzoyl peroxide (BPO) 5% topical gel containing glycerin and dimethicone. Subjects were randomized to receive this combination therapy in addition to either a tretinoin microsphere (RAM) gel at concentrations of either 0.04% or 0.1% or adapalene (AP) gel 0.1%. There was a trend toward better resolution of hyperpigmentation in the subjects receiving the clindamycin-BPO topical gel in combination with RAM gel 0.04%.
Taylor
Susan C
SC
College of Physicians and Surgeons, Columbia University, New York, New York, USA.
D000152:Acne Vulgaris / Q000150:complications / Q000188:drug therapy* / Q000208:ethnology*; D000068816:Adapalene; D001741:Black or African American; D000900:Anti-Bacterial Agents / Q000494:pharmacology / Q000627:therapeutic use; D044466:Asian People; D001585:Benzoyl Peroxide / Q000494:pharmacology / Q000627:therapeutic use; D002981:Clindamycin / Q000494:pharmacology / Q000627:therapeutic use; D003879:Dermatologic Agents / Q000494:pharmacology / Q000627:therapeutic use; D004129:Dimethylpolysiloxanes / Q000494:pharmacology; D004338:Drug Combinations; D004359:Drug Therapy, Combination; D005990:Glycerol / Q000494:pharmacology; D006630:Hispanic or Latino; D006801:Humans; D017495:Hyperpigmentation / Q000188:drug therapy* / Q000208:ethnology / Q000209:etiology / Q000517:prevention & control*; D007641:Keratolytic Agents / Q000494:pharmacology / Q000627:therapeutic use; D009281:Naphthalenes / Q000494:pharmacology / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D012880:Skin Pigmentation / Q000187:drug effects*; D014212:Tretinoin / Q000494:pharmacology / Q000627:therapeutic use